A Phase 1 Clinical Pharmacology Study of the Effects of a Single 4 Hour Intravenous Infusion of Bendavia (MTP-131) in Subjects With Stable New York Heart Association Class II-III Congestive Heart Failure Due to Left Ventricular Systolic Dysfunction

Trial Profile

A Phase 1 Clinical Pharmacology Study of the Effects of a Single 4 Hour Intravenous Infusion of Bendavia (MTP-131) in Subjects With Stable New York Heart Association Class II-III Congestive Heart Failure Due to Left Ventricular Systolic Dysfunction

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2015

At a glance

  • Drugs Elamipretide (Primary)
  • Indications Heart failure
  • Focus Adverse reactions
  • Acronyms PREVIEW
  • Sponsors Stealth BioTherapeutics
  • Most Recent Events

    • 16 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 26 May 2015 Positive results presented at the European Society of Cardiology (ESC) Heart Failure Congress 2015, according to a Stealth BioTherapeutics media release.
    • 24 Apr 2015 Planned End Date changed from 1 Apr 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top